Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.

Why Cassava Sciences Was Up 15% in May

Annovis Bio

There are better options for investors looking to profit from potential Alzheimer's disease treatments.

Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich

Arvinas Inc

Avadel Pharma

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Denali Therapeutics

Intra-Cellular Therapies

Karuna Therapeutics Inc

Neurocrine Biosciences

Prothena

SAGE Therapeutics

Supernus Pharmaceuticals

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ.

Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease

The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors.

Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data

Caladrius Biosciences

Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential).

Buying Cassava Sciences Ahead Of July Data

- Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months –

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease

The shares of Cassava Sciences Inc (NASDAQ: SAVA) have received a price target of $78 by B. Riley. These are the details.

SAVA Stock: $78 Target By B. Riley

AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to participate in the Sachs 4th Annual Neuroscience Innovation Forum, a virtual event held on April 28-30, 2021. The National Institute on Aging of the National Institutes of Health (NIH) has invited Cassava Sciences to showcase its scientific program at this event.

Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

Axsome Therapeutics

Biogen

Jazz Pharmaceuticals

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Alzheimer's Disease: 5 Stocks on Biotech Radars

- 9 Month Interim Analysis of Open-label Study to be Presented at  a Major Scientific Conference in July 2021 as an Oral Presentation -

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases

American Airlines

AMC Entertainment

GameStop

Zomedica

These high-flying stocks may soon reverse course.

5 Ultra-Popular Stocks to Avoid Like the Plague in April

Blink Charging

Being able to scout for future growth potential is a crucial pillar of investing success.

3 Best Contrarian Stocks to Buy Now

Bionano Genomics

Ocugen, Inc.

These stocks have been unstoppable since late December -- but will they stay that way?

5 High-Flying Stocks That Turned $200,000 Into More Than $1 Million in 3 Months

Is (SAVA) Outperforming Other Medical Stocks This Year?

Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?

Cassava Sciences simufilam produced an improvement in ADAS-cog scores of 1.6 points at 6 months.

Anavex And Cassava Sciences: Closer To An Understanding Of Alzheimer's Disease

AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021.

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

A potential new treatment for Alzheimer's disease could be worth billions.

Should You Buy Cassava Sciences Stock Now?

Birks Group

Express

Koss

Marathon Digital Holdings

Novavax

Sino-Global Shipping America

If nothing happens – and that's the hope – this article will be nothing but a good laugh. However, astute investors should at least know about these stocks that could crash.

7 High-Flying Stocks That Could Crash 20% or Even More

The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimers, has seen a 7% rise over the last ten trading days, while it is up 1% over the last five trading days. However, the stock has gained a whopping 666% year-to-date.

Can Rally In Cassava Sciences Stock Continue?

News for Cassava Sciences Inc Stock (SAVA)